Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

NCT03783078 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Merkel Cell Carcinoma

Interventions

DRUG: Pembrolizumab (MK-3475)

Sponsor

Merck Sharp & Dohme LLC